IMUNON INC (IMNN) Stock Price & Overview

NASDAQ:IMNN • US15117N7012

3.09 USD
-0.03 (-0.96%)
Last: Mar 10, 2026, 04:30 PM

The current stock price of IMNN is 3.09 USD. Today IMNN is down by -0.96%. In the past month the price decreased by -4.59%. In the past year, price decreased by -72.35%.

IMNN Key Statistics

52-Week Range2.99 - 41.2174
Current IMNN stock price positioned within its 52-week range.
1-Month Range3.06 - 3.62
Current IMNN stock price positioned within its 1-month range.
Market Cap
9.486M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-11.25
Dividend Yield
N/A

IMNN Stock Performance

Today
-0.96%
1 Week
-5.17%
1 Month
-4.59%
3 Months
-24.82%
Longer-term
6 Months -45.74%
1 Year -72.35%
2 Years -85.41%
3 Years -80.71%
5 Years N/A
10 Years N/A

IMNN Stock Chart

IMUNON INC / IMNN Daily stock chart

IMNN Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to IMNN. When comparing the yearly performance of all stocks, IMNN is a bad performer in the overall market: 94.68% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating
IMNN Full Technical Analysis Report

IMNN Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to IMNN. IMNN scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
IMNN Full Fundamental Analysis Report

IMNN Earnings

Next Earnings DateMar 26, 2026
Last Earnings DateNov 13, 2025
PeriodQ3 / 2025
EPS Reported-$1.16
Revenue Reported
EPS Surprise 37.00%
Revenue Surprise %
IMNN Earnings History

IMNN Forecast & Estimates

10 analysts have analysed IMNN and the average price target is 21.93 USD. This implies a price increase of 609.71% is expected in the next year compared to the current price of 3.09.


Analysts
Analysts80
Price Target21.93 (609.71%)
EPS Next Y77.34%
Revenue Next YearN/A
IMNN Forecast & Estimates

IMNN Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

IMNN Financial Highlights

Over the last trailing twelve months IMNN reported a non-GAAP Earnings per Share(EPS) of -11.25. The EPS increased by 54.38% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-14.33M
Industry RankSector Rank
PM (TTM) N/A
ROA -159.43%
ROE -351.06%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%73.84%
Sales Q2Q%N/A
EPS 1Y (TTM)54.38%
Revenue 1Y (TTM)N/A
IMNN financials

IMNN Ownership

Ownership
Inst Owners14.07%
Shares3.07M
Float3.04M
Ins Owners0.79%
Short Float %7.73%
Short Ratio4.65
IMNN Ownership

IMNN Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.3402.17B
AMGN AMGEN INC16.45203.213B
GILD GILEAD SCIENCES INC16.81182.029B
VRTX VERTEX PHARMACEUTICALS INC25.75117.075B
REGN REGENERON PHARMACEUTICALS16.5182.631B
ALNY ALNYLAM PHARMACEUTICALS INC43.2142.915B
INSM INSMED INC N/A30.852B
NTRA NATERA INC N/A29.086B
BIIB BIOGEN INC11.7227.626B
UTHR UNITED THERAPEUTICS CORP17.9423.193B
MRNA MODERNA INC N/A22.014B
EXAS EXACT SCIENCES CORP340.0819.797B
RVMD REVOLUTION MEDICINES INC N/A19.775B

About IMNN

Company Profile

IMNN logo image Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 25 full-time employees. The firm is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The firm is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.

Company Info

IPO: 1993-10-27

IMUNON INC

997 Lenox Dr Ste 100

Lawrenceville NEW JERSEY US

Employees: 25

IMNN Company Website

IMNN Investor Relations

Phone: 16098969100

IMUNON INC / IMNN FAQ

Can you describe the business of IMUNON INC?

Imunon, Inc. is a clinical stage oncology drug company. The company is headquartered in Lawrenceville, New Jersey and currently employs 25 full-time employees. The firm is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The firm is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.


What is the current price of IMNN stock?

The current stock price of IMNN is 3.09 USD. The price decreased by -0.96% in the last trading session.


Does IMUNON INC pay dividends?

IMNN does not pay a dividend.


What is the ChartMill rating of IMUNON INC stock?

IMNN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Should I buy IMNN stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IMNN.


What is the employee count for IMNN stock?

IMUNON INC (IMNN) currently has 25 employees.


Can you provide the upcoming earnings date for IMUNON INC?

IMUNON INC (IMNN) will report earnings on 2026-03-26, after the market close.